Clinical study on the effect of simvastatin on paraoxonase activity

Arzneimittel-Forschung/Drug Research

Volumn 57, Issue 10, 2007, Pages 647-653

  Muačević Katanec, Diana ^a   Bradamante, Vlasta ^a   Poljičanin, Tamara ^b   Reiner, Željko ^a   Babić, Zdravko ^c   Simeon Rudolf, Vera ^d   Katanec, Davor ^e  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University of Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^e UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Antioxidants; Aryldialkylphosphatase; CAS 79902 63 9; Cholesterol, high and low density apoprotein; Lipex ; Paraoxonase; Simvastatin, clinical study, effect on paraoxonase activity

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOTRIESTERASE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA; IN VIVO STUDY; LIPID ANALYSIS; LIPID PEROXIDATION; MALE;

EID: 35948935583     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296663     Document Type: Article

References (44)

1. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma. Curr Opin Lipidol. 1996;7:69-76.
2. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite Regulation of the Human Paraoxonase-1 Gene PON-1 by Fenofibrate and Statins. Mol Pharmacol. 2003;63:945-956.
3. Aviram M, Rosenblatt M, Bisgier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits HDL oxidation and preserves its functions: a possible role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
4. Furhman B, Volkova N, Aviram M. Oxidative stress increases the expression of the CD 36 scavenger receptor and cellular uptake of Ox-LDL in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase. Atherosclerosis. 2002;161:307-316.
5. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases1 (PON1), Q and R selectively decrease lipid peroxides in coronary and carotid atherosclerosic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101:2510-2517.
6. bin Ali Azhar, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med. 2003;34:824-829.
7. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Survival Study. Lancet. 1994;344:1383-1389.
8. Reiner Z. The role of hypolipemic drugs today. Medicus. 2002;11:37-47.
9. Deakin S, Leviev I, Guernier S, James RW. Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase. Arterioscler Thromb Vasc Biol. 2003;23: 2083-2089.
10. Karakaya A, Ibis S, Kural T, Kose SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact. 1999;118:193-200.
11. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003;107:2775-2779.
12. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid preoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA. 1992;89:10316-10320.
13. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, et al. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypersterolemic patients. Arterioscler Thromb Vasc Biol. 2000;20:2113-2119.
14. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock. 2004;21:210-221.
15. Aviram M, Rosenblatt M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol. 2005;16:393-399.).
16. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med. 2001;79:457-463.
17. Humbert R, Adler DA, Distecke CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
18. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins. Clin Genet. 1991;40:277-282.
19. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
20. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341-349.
21. Paragh G, Törocsik, Seres I, Harangi M, Illyés L, Balogh Z. Effect of short term treatment with simvastatin and atorvastatin on lipid paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 2004;20:1321-1327.
22. Beltowski J, Wojcicka G, Jemroz A. Effect of 3-hydroxy-3- methylglutarylcoenzyme A reductase inhibitors (statins) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol. 2004;43:121-127.
23. Stein EA, Myers, GL. Lipids, lipoproteins and apolipoproteins. In: Burtis CA, Ashwood ER, eds. Tietz textbook of clinical chemistry. 2nd ed. Philadelphia: W. B. Saunders; 1994. p. 1002-1081.
24. Nauck M, Marz W, Haas B, Wieland H. Homogeneous assay for direct determination of high density lipoprotein cholesterol evaluated. Clin Chem. 1996;42:424-429.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
26. Kostner GM, Molinari E, Pichler P. Evaluation of a new HDL2/HDL3 quantitation method based on precipitation with polyethylene glycol. Clin Chim Acta. 1985;148:139-147.
27. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet. 1983; 35:214-227.
28. Eckerson HW, Wyte C, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126-1138.
29. Gan KN, Smolen HW, Eckerson BN, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19:100-106.
30. StatSoft, Inc. (2006). Electronic Statistics Textbook. Tulsa, OK: StatSoft. Available from: http://www.statsoft.com/textbook/stathome.html
31. La Du BN. Structural and functional diversity of paraoxonases. Nat Med. 1996;2:1186-1187.
32. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21:473-480.
33. Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000; 86:406-411.
34. Harangi M, Seres I, Varga Z, Emri G, Szilvassy Z, Paragh G, et al. Atorvastatine ffect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur J Clin Pharmacol. 2004;60:685-691.
35. Paragh G, Torocsik D, Seres I, Harangi M, Illyes L, Balogh Z, et al. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 2004;20: 1321-1327.
36. Rural BV, Orem C, Uydu HA, Alver A, Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coron Artery Dis. 2004;15:277-283.
37. vanHimbergen TM, van Tits LJ, Voorbij HA, de Graaf J, Stalenhoef AF, Roest M. The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia. J Intern Med. 2005;258:442-449).
38. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON1) is inactivated by Ox-LDL and preserved by antioxidants. Free Radic Biol Med. 1999;26:892-904.
39. Rosenblat M, Hayek T, Hussein K, Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004;24:175-180.
40. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37:77-83.
41. Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F et al. Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005;54:142-150.
42. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gin-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995; 346:869-872.
43. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipid and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;11:1812-1818.
44. Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, et al. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients. Curr Med Res Opin. 2005;21:777-784.